Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,094.00
Ask: 12,096.00
Change: 46.00 (0.38%)
Spread: 2.00 (0.017%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RPT-Leaked letters show AstraZeneca vaccine commitment not as Thailand claimed

Tue, 20th Jul 2021 01:24

(Repeats item first carried late on Monday)

By Panu Wongcha-um

BANGKOK, July 19 (Reuters) - AstraZeneca Plc has
told Thailand it should be able to supply around 6 million doses
of its COVID-19 vaccine per month, leaked correspondence showed,
contradicting assertions by Thai officials that the government
had been promised 10 million.

Thailand's push for 10 million monthly doses comes as it
considers imposing vaccine export curbs on Thai-manufactured
vaccine to shore up domestic supplies, a move that could create
problems for its neighbours, some of which are battling similar
or more severe coronavirus crises.

But a June 25 letter by AstraZeneca to Thailand's health
minister showed that the Anglo-Swedish drugmaker had offered to
supply just 5-6 million doses a month to Thailand from a local
plant, or one third of the amount produced by its partner Siam
Bioscience, which is owned by Thailand's king.

"I hope you will be pleased that this is nearly twice the
volume we discussed during our meeting," AstraZeneca's vice
president of global corporate affairs, Sjoerd Hubben, said in
the letter, referring to a September 2020 meeting with Thai
officials.

At that meeting, the government officials estimated Thailand
required around 3 million doses per month, Hubben wrote.

The correspondence was first reported by Isara news agency
and later seen by Reuters.

AstraZeneca also explained at the September meeting that
Thailand had an opportunity to procure more via the
international COVAX vaccine-sharing scheme, Hubben said in the
letter.

Thailand, which never made supply deals with COVAX, instead
decided in January to buy 26 million doses from AstraZeneca and
another 35 million doses in May, the letter showed.

The director-General of the Thai Disease Control Department,
Opas Karnkawinpong, confirmed on Sunday that the letter was
authentic. He told reporters the 3 million figure had been a
rough estimate and Thailand had formally asked AstraZeneca in
April 2021 to provide 10 million monthly doses.

He did not say whether AstraZeneca had agreed to that, and
said it was understood that vaccine availability depended on
output and volume might need to be agreed on a monthly basis.

AstraZeneca had no comment on Monday on the leaked letter.

The letter also detailed AstraZeneca's supply commitments of
nearly 114 million doses elsewhere in Asia - a supply chain that
has become uncertain due to potential export restrictions by the
Thai government.

It planned to supply 50 million doses to Indonesia, 30
million to Vietnam, 16.5 million to the Philippines, 10 million
to Taiwan and 6.4 million to Malaysia, the letter showed.

Opposition lawmaker Wiroj Lakkhanaadisorn said Thai
authorities were prepared for neither a global supply shortage
nor the severe impact of variants of concern.

"The government was over-confident about the situation when
making these plans," he told Reuters on Monday. "They have been
very slow and careless."

Thailand has inoculated just 5.2% of its population so far.

A source with knowledge of Thailand's AstraZeneca agreement
said 61 million doses, or about a third of the local factory's
agreed output, would be delivered to Thailand overall, but no
monthly volume commitment had ever been agreed.
(Writing by Martin Petty
Editing by Mark Heinrich)

More News
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.